Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes.

导出 LinkOut

翻译打印收藏纠错

第一作者： Qi Ying,Lean

第一单位： a 1 Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania , Hobart, Tasmania, Australia.

作者： Qi Ying,Lean ^[1] ; Nuri,Gueven ^[2] ; Rajaraman D,Eri ^[1] ; Rajesh,Bhatia ^[3] ; Sukhwinder Singh,Sohal ^[4] ; Niall,Stewart ^[3] ; Gregory M,Peterson ^[5] ; Rahul P,Patel ^[1]

作者单位： a 1 Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania , Hobart, Tasmania, Australia. ^[1] b 2 Faculty of Pharmacy, University of Technology MARA, Puncak Alam , Selangor, Malaysia. ^[2] c 3 School of Health Sciences, Faculty of Health, University of Tasmania, Launceston , Tasmania, Australia. ^[3] d 4 Royal Hobart Hospital , Hobart, Tasmania, Australia. ^[4] e 5 Breathe Well Centre of Research Excellence for Chronic Respiratory Disease and Lung Ageing, School of Medicine, Faculty of Health, University of Tasmania , Hobart, Tasmania, Australia. ^[5] f 6 Health Services Innovation Tasmania, School of Medicine, Faculty of Health, University of Tasmania , Hobart, Tasmania, Australia. ^[6]

关键词 heparin inflammatory bowel disease low molecular weight heparin mechanism ulcerative colitis

主题词动物(Animals);消炎药(Anti-Inflammatory Agents);抗凝药(Anticoagulants);结肠炎, 溃疡性(Colitis, Ulcerative);肝素(Heparin);人类(Humans);治疗结果(Treatment Outcome)

DOI 10.1586/17512433.2015.1082425

PMID 26308504

发布时间 2022-04-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交